Some Troubling Unemployment Statistics
By now, most people have heard that the average national unemployment rate has fallen from close to 9.0% to 8.6%—the lowest in almost three years. While this may be cause for celebration, a closer inspection of other statistical findings is necessary to get a real picture of American unemployment (notwithstanding the fact that unemployment rates for African Americans and Hispanics are in double digits).
The source of these revealing stats was an article by Phyllis Korkki published in the New York Times this past New Year’s Day entitled “The Year of the Multitaskers’ Revenge” According to Ms. Korkki, while the overall unemployment rate is 8.6%, the jobless rate for persons who earned a college degree is 4.4% while the rate for those with a high school diploma is 8.8%. The unemployment rate for those individuals who did not graduate from high school is a staggering 13.2%. However, a more troubling statistic offered by Ms. Korkki is that less than 30% of United States population of 25 years or older has a bachelors or higher degree. To make matters worse, 30% of jobless Americans have been unemployed for a year or more.
Ms. Korrki contends that large groups of American will continue to be unemployed or underemployed unless more training and educational opportunities become available to the public. Further she asserts that if the long term unemployed do not get some government help than this groups risks falling so far behind that it will never be able to catch up.
Most analysts predict that unemployment rates in the US will remain high for five years or more. Like Korkki, I believe that the only way to reduce unemployment among non-college graduates is to fund programs that are designed to retrain workers for jobs in emerging technologies. Further, bringing manufacturing jobs from overseas back to the US will also help!
Until next time...
Good Luck and Good Job Hunting!!!!!!!!!!
Much has been written about the emerging markets in China. While there are likely thousands of business article and white papers on China’s economic expansion, I was unable to find a single source that provided me with some vital economic and social statistics to explain China’s rise as an economic power; that is until I received OnWisconsin, a quarterly publication from my alma mater the University of Wisconsin-Madison.
The New Jersey Governors Office 
I mistakenly received the Wall Street Journal (WSJ) rather than the NY Times today and while I think that the WSJ is a great example of unabashedly biased journalism, there was an article in the publication about today’s job market that contained some interesting statistics.
While big pharma companies continue to shed jobs, there are some indications that the biotechnology industry is beginning to pick up some steam. For example, Boehringer Ingelheim (both a drug development and biomanufacturing company) is planning a 
Unlike many of its big pharma competitors which are shuttering US manufacturing facilities, MedImmune, the biologics division of London-based pharmaceutical giant AstraZeneca, Friday, .jpg)
There are rumors that companies are hiring again and that pharmaceutical jobs may begin to make a comeback over the next six months to a year. This may be a real possibility based on a new report released yesterday the outplacement firm Challenger, Gray and Christmas, Inc..jpg)
Japanese drug maker Takeda Pharmaceuticals announced today that it will slash almost .jpg)
For the past year or so, I have been focusing on the downsizing and layoffs taking place at big pharmaceutical companies. The unprecedented size and scope of these massive layoffs have overshadowed the downsizing and job loss taking place at small to mid-size public and private biopharmaceutical companies. In contrast with most fully-integrated vertical pharmaceutical companies that are flush with cash, most biotech companies—even the likes of Amgen, Genentech, Gilead and others—don’t have the cash reserves to maintain operations in a down economy or when a drug candidate fails in clinical development. This coupled with the lack of venture and private equity capital has been causing biopharmaceutical employees to lose sleep in recent months.
, or 12 percent of its work force, by 2014 to cut costs as it reported disappointing fourth quarter earnings. The job cuts will be made across all regions and divisions and were necessary because some of the company’s major products including the child asthma medication Pulmicort, which made sales of $1.3 billion in 2009, and breast cancer treatment Arimidex, with $1.92 billion in sales will be losing patent protection in the near future.
today reports that spending on direct-to-consumer pharmaceutical advertising came bounding back in the third quarter —rising 15 percent to $1.16 billion, according to .jpg)
Reuters reports 
.jpg)
Forbes Magazine released its 
In the February issue of .jpg)
